GLP1R and inflammatory bowel disease: Taken together with recent information about possible anti-inflammatory effect of GLP-1 we suggest that developing drugs targeting the incretin system may be potential additive therapy to IBD treatment resulting in less adverse effects and better clinical outcomes.